Stock Updates

How has Celgene Corporation:(NASDAQ:CELG) performed recently?

Celgene Corporation (NASDAQ: CELG) is a large market cap stock with a market cap of 78255.15. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 48.5, a forward P/E of 14.34 and EPS of 2.07. At a stock price of 100.25 (-0.45%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 15.70%, more recently this last year it has grown by -18.80%. The next year growth is going to be about 23.32% and more long-term 22.06% after five years. EPS growth quarter over quarter is 15.00%. Sales growth for the past five years have been 20.60% and sales growth quarter over quarter is 20.70%.

For performance, Celgene Corporation the past week has seen a gain of 5.69%. For the last month performance for Celgene Corporation is -6.82%. While the last quarter is -1.83% and half year, -14.77%. Finally for the year, performance is -15.63%.

The 52-week high for Celgene Corporation, is at -28.76%, and for the 52-week low it comes to a value of 7.82%. The 20-day simple moving average is -2.34% and -6.96% for the 200-day simple moving average.

Volatility for the week is at 2.14%, and for the month it is 2.31%. Celgene Corporation, has a target price of 136.38.

In terms of debt, long term debt/equity is 2.81, and for total debt/equity Celgene Corporation has 0. The gross margin is 95.60%, while operating margin is 24.50%, the profit margin is 17.40%. The current ratio is 4.6 and the quick ratio is 4.3.

Insider ownership is at 0.20%, with instituitional ownership at 80.40%. Celgene Corporation has a payout ratio of 0.00%. With the total shares outstanding coming to 780.6. The shares float is 772.43, with the float short at 1.09%, with short ratio coming to 1.92.

In terms of returns, the return on assets see Celgene Corporation, get 6.90%, with its returns on investment at 8.90%. Return on equity is 29.70%. So will the investors see the target price of 136.38, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment